General Information

We are a rapidly growing diagnostics company with proprietary molecular and bioinformatics technology that we are deploying to change the management of genetic disease worldwide. Our novel molecular assays reliably measure many informative regions across the genome from samples as small as a single cell. Our statistical algorithms combine these measurements with data available from the broader scientific community to detect a wide range of serious conditions with best-in-class accuracy and coverage. Our technology has been proven clinically and commercially in the prenatal testing space. We believe this success can be translated into the liquid biopsy space, and we are developing products for a number of oncology applications. In addition to our direct sales force in the United States, which we are continuing to expand, we have a global network of over 70 laboratory and distribution partners, including many of the largest international laboratories. We are enabling even wider adoption of our technology by introducing a global cloud-based distribution model. We have launched seven molecular diagnostic tests since 2009, and we intend to launch new products in prenatal testing and oncology in the future.

Employees: 674
Founded: 2003
Contact Information
Address 201 Industrial Road, Suite 410, San Carlos, CA 94070, US
Phone Number (650) 249-9090
Web Address
View Prospectus: Natera
Financial Information
Market Cap $871.7mil
Revenues $179.4 mil (last 12 months)
Net Income $-5.5 mil (last 12 months)
IPO Profile
Symbol NTRA
Exchange NASDAQ
Shares (millions): 10.0
Price range $18.00 - $18.00
Est. $ Volume $180.0 mil
Manager / Joint Managers Morgan Stanley/ Cowen and Company/ Piper Jaffray
CO-Managers Baird/ Wedbush Pacgrow
Expected To Trade: 7/2/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change